Eli Lilly's market share in India's weight‑loss drug market fell to 56% in March from 61% in February. Novo Nordisk's market share remained steady at 25%. Indian generic drugmakers have launched 26 ...

The rapid entry of semaglutide generics is beginning to weigh on the growth of Eli Lilly’s tirzepatide brand Mounjaro, even as the broader market expands, data from pharma market intelligence and data ...

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our ...

Patients in Canada have been paying between $300 and $400 a month for Ozempic and Wegovy, depending on the prescribed dose You can save this article by registering for free here. Or sign-in if you ...

Pharman giant Biocon on Thursday named longtime executive Shreehas Tambe as its Managing Director and CEO, effective 1 April, as the Indian drugmaker completes the integration of its biologics arm to ...

Pharmaceutical companies have launched generic versions of Ozempic in India, beating Canadians to market despite the drugs being legal in Canada for nearly three months. Novo Nordisk’s remaining ...

Sun Pharmaceutical, Dr. Reddy’s Laboratories, Zydus Life Sciences, and Glenmark Pharmaceuticals rolled out generic versions of Semaglutide on March 21, following the expiration of the patent on the ...

https://www.thehindubusinessline.com/companies/generic-versions-of-novo-nordisks-semaglutide-begin-to-flow-priced-50-80-lower-than-the-innovator/article70769849.ece ...

Did our AI summary help? At least a dozen large Indian drugmakers are set to roll out copies of Novo Nordisk A/S’s blockbuster weight-loss drugs as soon as the patent expires Friday, crashing prices ...

India’s weight-loss drug market is on the verge of a price shake-up. In days, domestic drugmakers are set to launch cheaper versions of semaglutide, the GLP-1 (glucagon-like peptide-1) therapy popular ...

Strides Pharma Science has agreed to acquire and in license a portfolio of branded generic medicines from Sandoz, strengthening its presence across Sub Saharan Africa. The deal, valued at about 12 ...